Hepatitis C Virus Infection



  • The indications for apheresis are hepatitis C virus (HCV) serotype 1 cases with HCV-RNA more than 100 kIU/mL and interferon-α (IFN) resistive.

  • Plasma fractionator (2nd filter) of double filtration plasmapheresis (DFPP) is equivalent to Cascadeflo™ EC-50 W with a size pore of 30 nm.

  • Immediately after DFPP, HCV starts showing a rebound phenomenon. The timing of IFN administration has to be as soon as possible.

  • When patients have a history of splenectomy, catheter infection tends to cause severe septicemia.


Sustain Virological Response Fibrinogen Level Rebound Phenomenon High Sustain Virological Response Virus Removal 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Noiri E, Nakao A, Oya A, Fujita T, Kimura S (2001) Hepatitis C virus in blood and dialysate in hemodialysis. Am J Kidney Dis 37:38–42PubMedGoogle Scholar
  2. 2.
    Yamashita T, Arai K, Sakai A, Mizukoshi E, Sakai Y, Kagaya T, Nakamoto Y, Honda M, Wada T, Yokoyama H, Kaneko S (2006) Virological effects and safety of combined double filtration plasmapheresis (DFPP) and interferon therapy in patients with chronic hepatitis C: a preliminary study. Hepatol Res 36:167–175PubMedCrossRefGoogle Scholar
  3. 3.
    Fujiwara K, Kaneko S, Kakumu S, Sata M, Hige S, Tomita E, Mochida S (2007) Virus Reduction Therapy Study Group: Double filtration plasmapheresis and interferon combination therapy for chronic hepatitis C patients with genotype 1 and high viral load. Hepatol Res 37:701–710PubMedCrossRefGoogle Scholar
  4. 4.
    Hijikata M, Shimizu YK, Kato H, Iwamoto A, Shih JW, Alter HJ, Purcell RH, Yoshikura H (1993) Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. J Virol 67:1953–1958PubMedGoogle Scholar
  5. 5.
    Omata M, Yokosuka O, Takano S, Kato N, Hosoda K, Imazeki F, Toda M, Ito Y, Ohto M (1991) Resolution of acute hepatitis C after therapy with natural beta interferon. Lancet 338:914–915PubMedCrossRefGoogle Scholar

Copyright information

© Springer Japan 2014

Authors and Affiliations

  1. 1.Department of Hemodialysis & ApheresisUniversity Hospital, The University of TokyoTokyoJapan

Personalised recommendations